Abstract
Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) represent 95% of all mCRC cases and are characterized by resistance to PD-1 or PD-L1 checkpoint inhibition. Liver metastatic disease has been associated with decreased responses to immunotherapy in non-small cell lung cancer and melanoma. However, the impact of metastatic disease to the liver in MSS mCRC on treatment response has not been investigated in the setting of PD-1 or PD-L1 targeting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
